

## Deep brain stimulation: current and future perspectives

NASIR RAZA AWAN, M.B.B.S., F.C.P.S., ANDRES LOZANO, M.D., PH.D.,  
AND CLEMENT HAMANI, M.D., PH.D.

*Division of Neurosurgery, Toronto Western Hospital, University of Toronto*

Deep brain stimulation (DBS) has been used to treat various neurological and psychiatric disorders. Over the years, the most suitable surgical candidates and targets for some of these conditions have been characterized and the benefits of DBS well demonstrated in double-blinded randomized trials. This review will discuss some of the areas of current investigation and potential new applications of DBS. (DOI: 10.3171/2009.4.FOCUS0982)

**KEY WORDS** • **deep brain stimulation** • **movement disorders** •  
**epilepsy** • **psychiatry** • **brain-machine interface**

**D**EEP brain stimulation is one of the most important therapies in functional neurosurgery to date. In addition to its established role for the treatment of movement disorders, promising results have now been reported in epilepsy and psychiatric diseases. The reversibility and low profile of side effects of this therapy have made it an attractive alternative to conventional radiofrequency lesions. As a consequence, potential new applications are currently being proposed for diseases previously considered out of the realm of neurosurgical therapies.

This review will focus on areas of current and future investigation of DBS, including its potential use as a component of brain-machine interfaces. Postoperative MR images with electrodes implanted in different targets used for the treatment of movement disorders are shown in Fig. 1.

### Movement Disorders

#### *Parkinson Disease*

The introduction of DBS as a therapeutic tool for advanced PD has revolutionized the clinical management of this condition. Due to its safety profile and efficacy, DBS evolved from a last-resort therapeutic option to a modality that is now routinely offered to patients. Over the years, surgical candidates and the outcome expected with this procedure became well established. In fact, there is now Class-I evidence showing that STN stimulation is more effective than the best medical therapy.<sup>20,148</sup> Overall, the

improvement in PD that might be expected with surgery is similar to that provided by levodopa without the associated involuntary movements (dyskinesias).<sup>1,20,41,55,59,108,148</sup> As the disease progresses, however, nondopaminergic symptoms (gait, postural instability, depression, and sleep disorders, among others) become more prominent, leading to a significant increase in morbidity. To overcome some of these problems, the use of different surgical targets has been advocated. Perhaps the most promising application of DBS in this regard involves the use of PPN stimulation for the treatment of gait and postural instability.<sup>85,104,123,149</sup> In a preliminary report, Stefani and colleagues<sup>123</sup> have shown a significant improvement in the axial symptoms of PD after PPN DBS. Recent studies suggest that this procedure may be suited for the treatment of falls and freezing.<sup>100</sup> In addition to motor symptoms, our group reported an improvement in rapid eye movement sleep in patients with PD treated with PPN DBS.<sup>74</sup> In the future, a tailored approach to patients' specific symptoms may be possible.

Another major challenge will be to devise therapies that not only treat the symptomatology of PD but are also able to arrest the progression of the disease. Although it has been hypothesized that early surgical interventions could reduce nigral degeneration,<sup>107</sup> this hypothesis has not been clearly demonstrated so far. To date, outcome of the first clinical trials using DBS in patients with early-stage PD have shown that postoperative outcome was as good as that in regular surgical candidates.<sup>114</sup> Whether treatment will change the progression of the disease in these patients will likely be established in the future.

#### *Dystonia and Tremor Disorders*

Pallidal stimulation is currently considered the main surgical treatment for dystonia. In patients with primary

*Abbreviations used in this paper:* DBS = deep brain stimulation; ECoG = electrocorticography; IPG = implantable pulse generator; PD = Parkinson disease; PPN = pedunculo-pontine nucleus; STN = subthalamic nucleus.




Fig. 1. Magnetic resonance images of DBS electrodes (arrows) implanted in the STN (A), globus pallidus internus (GPI; B), and ventralis intermedius nucleus (Vim) of the thalamus (C). RN = red nucleus. Bars = 10 mm. Reprinted from the **Encyclopedia of Neuroscience**, Laxton AW, Hamani C, Moro E, Lozano AM, Deep brain stimulation and movement disorder treatment, 369–373, 2009,<sup>65</sup> with permission from Elsevier.

forms of the disease, improvement rates are typically 40–70%.<sup>4,17,24,40,50,54,60,61,64,122,141,143,144</sup> Well-designed controlled studies have now shown that stimulation is more effective than sham treatment.<sup>64,143</sup> Overall, patients with secondary dystonias do not respond as well to DBS therapy. Because secondary dystonias comprise a group of different entities, an important aspect in future DBS trials will be to determine conditions associated with a good postoperative outcome. As an example, patients with tardive dystonias and pantothenate kinase–associated neurodegeneration respond well to pallidal DBS.<sup>14,122,129,132,151</sup> In contrast, postanoxic, postencephalitic, perinatal, and poststroke dystonias all appear to indicate a poor prognosis.<sup>24,32,60,122</sup> Another factor that needs to be addressed is the role of different surgical targets. For primary dystonias, the most commonly used target is the globus pallidus internus, although good postoperative results have also been reported after STN DBS.<sup>56,64,143,144</sup> For secondary dystonias, a good outcome has been reported with both thalamic and pallidal DBS.<sup>14,40,122,129,132,151</sup>

Deep brain stimulation is also used to treat various forms of tremor. In patients with essential tremor, symptom improvement has been well documented.<sup>57,76,105,115,116,126,127</sup> This improvement results in a better quality of life, particularly in patients who have long-term control of tremor and no associated morbidity from other diseases.<sup>43,44,79,105,126</sup> More variable and unpredictable results are noted with DBS for multiple sclerosis. Because the disorder is associated with a collection of debilitating symptoms, improvement in tremor does not always reflect lifestyle changes.<sup>9,10,47</sup>

### Pain

The long-term outcome of DBS for the treatment of chronic neuropathic pain is quite variable, with most studies showing a response in 25–60% of patients (40–50% reduction in visual analog scale scores).<sup>21,48,63,73,106,131</sup> Part of this variability may be attributed to the surgical target and the clinical conditions treated. The main structures targeted for chronic pain are the thalamus and the periaqueductal/periventricular gray matter. Overall, thalamic DBS has been suggested to be more effective for neu-

ropathic pain, whereas nociceptive pain responds better to stimulation in the periaqueductal/periventricular gray matter.<sup>72,73,147</sup> Coffey<sup>16</sup> has recently reported on the outcome of 2 open multicenter studies sponsored by one of the manufacturers of the stimulators (Medtronic). These trials were completed in 1993 and 1998, showing an approximate response rate of only 20%.<sup>16</sup>

A recent promising application of DBS in the pain field is its use for the treatment of cluster headaches and trigeminal autonomic cephalalgias. Studies with hypothalamic stimulation showed a decrease in the intensity and/or frequency of headaches.<sup>30,68,69,83,113,121</sup> Controlled trials with a higher number of patients and longer follow-up durations are still necessary to ascertain the therapeutic role of DBS for the treatment of these conditions.

### Epilepsy

The main DBS targets investigated for the treatment of epilepsy are the centromedian nucleus of the thalamus,<sup>137–140</sup> the anterior thalamic nuclei,<sup>6,46,53,67,75,95</sup> and the hippocampus.<sup>13,128,135,136,146</sup> Deep brain stimulation was also explored in the subthalamic nucleus,<sup>8,15,42,67,77,142</sup> locus ceruleus,<sup>25</sup> caudate nucleus,<sup>120</sup> and mammillary bodies.<sup>23</sup> Candidates for the procedure often have frequent disabling seizures, a significant impairment in quality of life, refractoriness to treatment with multiple antiepileptic medications, and either bilateral/multifoci seizures or a nonidentifiable seizure focus. Overall, centromedian nucleus DBS has been suggested to be more effective against generalized tonic-clonic seizures, atypical absence seizures, and Lennox-Gastaut syndrome.<sup>134,137,140</sup> Anterior thalamic nuclei and hippocampal DBS have been primarily used for the treatment of partial epilepsies.<sup>6,13,46,53,67,75,95,128,135,136,146</sup>

In general, results of nonblinded studies in various targets have been very promising, but sometimes not corroborated by blinded trials comparing the frequency of seizures in “on” and “off” stimulation conditions.<sup>26,128</sup> A new wave of optimism has been recently brought to the field by a recent multicenter study. The “stimulation of the anterior nucleus of the thalamus in epilepsy” (SANTE)

## Current and future perspectives of DBS

trial collected data from 110 patients treated at 17 US centers. Double-blinded assessments after 3 months of therapy have shown a significantly higher reduction in the frequency of seizures as compared with sham treatment (38 vs 14.5%, respectively). At long term, 40% of the patients had a 50% or greater reduction in seizure rate ([http://www.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1228746390966&format=print&lang=en\\_US](http://www.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1228746390966&format=print&lang=en_US))

Also promising has been the development of trials using closed loop stimulation.<sup>28,29,58,87,94,125</sup> This method involves the delivery of current in response to cues, events, or commands, in contrast to the round-the-clock stimulation delivery in open loop trials. After a seizure is detected, stimulation is delivered to either the seizure focus (local stimulation) or a distant region somehow integrated to epileptogenic circuits (such as the anterior thalamic nucleus).<sup>93,94</sup> Preliminary reports of small case series have shown significant improvements with the use of these systems. A controlled clinical trial is currently underway and results are greatly anticipated.<sup>125</sup>

### Psychiatric Disorders

One of the most promising recent applications of DBS is in the treatment of psychiatric diseases. Three main psychiatric conditions have thus far been considered for DBS treatment: Tourette syndrome, obsessive-compulsive disorder, and depression.

In Tourette syndrome, both thalamic and pallidal DBS have proved successful in reducing the frequency of tics.<sup>3,19,22,49,80,117,118,133,145,150</sup> For obsessive-compulsive disorder, the main targets are the anterior capsule and STN; stimulation of the caudate nucleus and the inferior thalamic peduncle has also been reported.<sup>2,7,27,36,37,52,81,91,92</sup> Overall, 40–60% of patients treated with capsular DBS had an adequate response to surgery (~33% reduction in Yale-Brown Obsessive Compulsive Scale scores).<sup>2,36,37,91,92</sup> In the initial reports using this technique, high DBS settings were needed to control the patients' symptomatology, requiring a high number of battery changes.<sup>91,92</sup> In recent studies, however, lower energy expenditure has been reported as the target moved ventral and posterior, closer to the ventral striatum/nucleus accumbens.<sup>36,37</sup> A similar outcome has been reported after STN DBS. In a recent well-designed controlled study, stimulation was significantly more effective than sham treatment.<sup>81</sup>

Deep brain stimulation targets used to treat refractory depression include the subgenual cingulate gyrus,<sup>78,84</sup> anterior capsule,<sup>82</sup> inferior thalamic peduncle,<sup>51</sup> and nucleus accumbens.<sup>112</sup> Results from nonblinded studies using the first 2 regions prompted the development of multicenter clinical trials, which are now underway. Of the patients receiving subgenual cingulate gyrus DBS during initial studies, 50–60% responded to the therapy (50% reduction in Hamilton Rating Scale for Depression scores).<sup>78,84</sup> Similarly, response rates to capsular DBS are typically 40–55%.<sup>82</sup> If stimulation proves to be an effective therapy for depression, the impact from an economic and epidemiological standpoint will be significant. Depression has a 6-month prevalence of approximately 5%. Although

most patients respond favorably to treatment, as many as 30–40% (1.5% of the general population) will experience chronic and refractory forms of this disease. Most of these patients are unable to work. Improvements in quality of life and an eventual return to the labor market after DBS would have a major impact.

### Emerging Indications of DBS

Deep brain stimulation has now been suggested as an emergent treatment for various conditions, including hypertension,<sup>33–35</sup> minimally conscious states,<sup>111</sup> obesity,<sup>38,39</sup> memory improvement,<sup>39</sup> aggressiveness,<sup>31,45,62</sup> and drug addiction.<sup>124</sup> Preliminary data are now available for some of these indications.

Green et al.<sup>33–35</sup> have shown that periaqueductal/periventricular gray matter DBS could modulate blood pressure in patients with chronic neuropathic pain. Depending on the stimulation site, an increase or decrease in blood pressure was recorded. In this context, the authors advocated stimulation as a potential treatment for both hypertension and orthostatic hypotension.<sup>33–35</sup>

Although neuromodulation therapies have been previously attempted for vegetative states,<sup>130,152,153</sup> Schiff et al.<sup>111</sup> have recently demonstrated in a double-blind study that thalamic DBS was able to modulate behavioral responsiveness in a patient who was in a minimally conscious state. We have recently reported on a morbidly obese patient treated with hypothalamic/forniceal DBS<sup>9</sup> in whom stimulation evoked detailed autobiographical memories and improved associative memory tasks.<sup>39</sup> That study led to future investigations on the potential use of DBS for conditions associated with memory impairment.

For aggressiveness, encouraging results have been reported with the use of hypothalamic DBS in a few patients with mental retardation and eventually self-mutilating behaviors.<sup>31,45,62</sup>

### Future Perspectives for DBS Devices

Current DBS systems include multicontact intracranial electrodes, adaptors to fix the electrodes in place, an IPG, and extension cables to connect the DBS electrode(s) to the IPG. Programming of the devices is performed by telemetry via a personal digital assistant-like system. As practiced today, stimulation adjustment requires several visits to the clinic so that optimal settings can be ascertained. Each of the electrode contacts has to be tested for efficacy and side effects, and interactions between stimulation and medications need to be carefully managed. In the future, it will be necessary to develop ways of reducing the time required for programming, perhaps through electrophysiological or imaging indicators. These indicators may provide a more objective way of assessing the effects of DBS, allowing for a quicker screening of potential combinations of contacts/stimulation settings. Also important would be the ability to program pulse generators through remote access, telephone lines, or the Internet. Some of this technology is available for cardiac pacemakers and currently in use in recent trials investigating the role of stimulation for epilepsy (see below).

Another area of recent advance relates to the power source for DBS. As currently used for movement disorders, the lifespan of regular IPGs is ~ 5 years.<sup>11</sup> When higher charge densities are needed, however, the frequent replacement of the pulse generators is of significant concern. Rechargeable batteries have been used for spinal cord stimulation and are now commercially available for DBS. Although no long-term studies have been conducted, a lifespan of up to 9 years has been advertised for DBS rechargeable batteries (depending on usage and the number of times the patient needs to recharge the IPG). Also of interest would be the possibility of miniaturizing pulse generators and DBS systems, so they could fit the confines of a bur hole or be overlaid on the skull. This miniaturization would likely decrease the adverse effects related to therapy, because extension cables would no longer be necessary. Future technological developments will also likely lead to newer designs of electrode arrays and geometry so that efficacy may be optimized with a reduction in adverse effects.

### Deep Brain Stimulation and Brain-Machine Interfaces

In recent years, the use of neuroprosthetic devices to enhance or replace nervous system function has grown considerably. In this field, brain-machine interfaces are considered promising future tools for the management of patients with neurological conditions, particularly those who are severely handicapped.<sup>12,18,66,70,89,99</sup> The process involves collecting, analyzing, and translating neural activity to drive machines or actuators.<sup>66,99</sup> The first step required is signal detection. Signals used (to date) are most commonly electrical, including those generated by single or multiunit cell recordings, local field potentials, EcoG, and electroencephalography. Changes in the pattern and rate of neuronal firing, brain rhythms, and oscillatory activity may all provide data that can be used by the interfaces. Once interpreted, information translated is fed to an actuator (robotic arm). After the action, feedback needs to be provided to compensate for potential errors and eventually improve performance in future trials.

A question that then emerges is whether DBS could be used as a component of brain-machine interfaces. Steps required for processing data and delivering closed loop stimulation are somewhat similar to those used by brain-machine interfaces. Components of the so-called external responsive neurostimulation system used in epilepsy include depth and strip electrodes, a pulse generator, and external devices (programmer, data transmitter, and telemetry wand).<sup>29,87</sup> Electrodes initially record local field potentials or cortical activity. Signals are then sent to a microprocessor in the generator, which stores ECoG signals. Upon detection of epileptiform events, responsive therapy (electrical stimulation) is delivered. Signals are then once again recorded and processed to assess whether epileptogenic activity is still present. If so, the patient receives new bursts of electrical stimulation. External responsive neurostimulation systems are readily assessable using telemetry. With a wand and a notebook, care providers can look at online ECoG signals and con-

duct test stimulation to assess the effectiveness of specific stimulation paradigms. In summary, the system is capable of detecting signals, analyzing information, delivering a therapy, and assessing efficacy.

Using DBS systems as part of brain-machine interfaces would involve a few positive aspects. Electrodes have been safely implanted in various brain targets, causing little inflammation.<sup>88,102</sup> These electrodes are long-lasting, with the lifespan of DBS systems currently limited by the battery life. Local field potentials have been systematically recorded from DBS electrodes<sup>90,96,97,109</sup> and could be theoretically used to feed brain-machine interfaces. A major disadvantage would be the inability to record single or multiunit cell activity from one or different sources. This disadvantage, in theory, could lead to a decrease in spatial and temporal resolution of the signal, potentially compromising the degrees of freedom and complexity of actions to be performed by the actuator. Nonetheless, signals from local field potentials mainly recorded from the cortex have been successfully used to predict motor patterns.<sup>5,71,86,101,103,110,119</sup> It has recently been shown that neuronal ensembles in subcortical motor regions (thalamus and STN) can provide informative signals to control a brain-machine interface.<sup>98</sup> Whether local field potentials recorded through DBS electrodes will turn into a practical means of driving brain-machine interfaces remains to be proven.

### Conclusions

As the number of patients using DBS devices increases, ideal surgical candidates and targets for each application of this therapy will likely be established. In the future, we expect to see an expansion in the number of diseases treated with DBS, as functional imaging and translational research help us to identify discrete areas of the brain that may be targeted in different disorders. Future technological advances in hardware components will hopefully lead to an increase in efficacy with a reduction in adverse effects of this therapy.

### Disclosure

Andres Lozano, M.D., Ph.D., is a consultant to Medtronic, St. Jude Medical, and Boston Scientific. Clement Hamani, M.D., Ph.D., is a consultant to St. Jude Medical.

### References

1. Deep-Brain Stimulation for Parkinson's Disease Study Group: Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. **N Engl J Med** **345**:956–963, 2001
2. Abelson JL, Curtis GC, Sagher O, et al: Deep brain stimulation for refractory obsessive-compulsive disorder. **Biol Psychiatry** **57**:510–516, 2005
3. Ackermans L, Temel Y, Cath D, et al: Deep brain stimulation in Tourette's syndrome: two targets? **Mov Disord** **21**:709–713, 2006
4. Alterman RL, Shils JL, Miravite J, et al: Lower stimulation frequency can enhance tolerability and efficacy of pallidal deep brain stimulation for dystonia. **Mov Disord** **22**:366–368, 2007
5. Andersen RA, Musallam S, Pesaran B: Selecting the signals

## Current and future perspectives of DBS

- for a brain-machine interface. **Curr Opin Neurobiol** **14**:720–726, 2004
6. Andrade DM, Zumsteg D, Hamani C, et al: Long-term follow-up of patients with thalamic deep brain stimulation for epilepsy. **Neurology** **66**:1571–1573, 2006
  7. Aouizerate B, Cuny E, Martin-Guehl C, et al: Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. **J Neurosurg** **101**:682–686, 2004
  8. Benabid AL, Minotti L, Koudsie A, et al: Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luyi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. **Neurosurgery** **50**:1385–1392, 2002
  9. Berk C, Carr J, Sinden M, et al: Assessing tremor reduction and quality of life following thalamic deep brain stimulation for the treatment of tremor in multiple sclerosis. **J Neurol Neurosurg Psychiatry** **75**:1210–1211, 2004
  10. Berk C, Carr J, Sinden M, et al: Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life. **J Neurosurg** **97**:815–820, 2002
  11. Bin-Mahfoodh M, Hamani C, Sime E, et al: Longevity of batteries in internal pulse generators used for deep brain stimulation. **Stereotact Funct Neurosurg** **80**:56–60, 2003
  12. Birbaumer N, Cohen LG: Brain-computer interfaces: communication and restoration of movement in paralysis. **J Physiol** **579**:621–636, 2007
  13. Boon P, Vonck K, De Herdt V, et al: Deep brain stimulation in patients with refractory temporal lobe epilepsy. **Epilepsia** **48**:1551–1560, 2007
  14. Castelnau P, Cif L, Valente EM, et al: Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. **Ann Neurol** **57**:738–741, 2005
  15. Chabardes S, Kahane P, Minotti L, et al: Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. **Epileptic Disord** **4** (3 Suppl):S83–S93, 2002
  16. Coffey RJ: Deep brain stimulation for chronic pain: results of two multicenter trials and a structured review. **Pain Med** **2**:183–192, 2001
  17. Coubes P, Cif L, El Fertit H, et al: Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. **J Neurosurg** **101**:189–194, 2004
  18. Daly JJ, Wolpaw JR: Brain-computer interfaces in neurological rehabilitation. **Lancet Neurol** **7**:1032–1043, 2008
  19. Dehning S, Mehrkens JH, Muller N, et al: Therapy-refractory Tourette syndrome: beneficial outcome with globus pallidus internus deep brain stimulation. **Mov Disord** **23**:1300–1302, 2008
  20. Deuschl G, Schade-Brittinger C, Krack P, et al: A randomized trial of deep-brain stimulation for Parkinson's disease. **N Engl J Med** **355**:896–908, 2006
  21. Dieckmann G, Witzmann A: Initial and long-term results of deep brain stimulation for chronic intractable pain. **Appl Neurophysiol** **45**:167–172, 1982
  22. Diederich NJ, Kalteis K, Stamenkovic M, et al: Efficient internal pallidal stimulation in Gilles de la Tourette syndrome: a case report. **Mov Disord** **20**:1496–1499, 2005
  23. Duprez TP, Serieh BA, Raftopoulos C: Absence of memory dysfunction after bilateral mammillary body and mammillothalamic tract electrode implantation: preliminary experience in three patients. **AJNR Am J Neuroradiol** **26**:195–198, 2005
  24. Eltahawy HA, Saint-Cyr J, Giladi N, et al: Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. **Neurosurgery** **54**:613–621, 2004
  25. Feinstein B, Gleason CA, Libet B: Stimulation of locus coeruleus in man. Preliminary trials for spasticity and epilepsy. **Stereotact Funct Neurosurg** **52**:26–41, 1989
  26. Fisher RS, Uematsu S, Krauss GL, et al: Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures. **Epilepsia** **33**:841–851, 1992
  27. Fontaine D, Mattei V, Borg M, et al: Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. **J Neurosurg** **100**:1084–1086, 2004
  28. Fountas KN, Smith JR: A novel closed-loop stimulation system in the control of focal, medically refractory epilepsy. **Acta Neurochir Suppl** **97**:357–362, 2007
  29. Fountas KN, Smith JR, Murro AM, et al: Implantation of a closed-loop stimulation in the management of medically refractory focal epilepsy: a technical note. **Stereotact Funct Neurosurg** **83**:153–158, 2005
  30. Franzini A, Ferroli P, Leone M, et al: Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. **Neurosurgery** **52**:1095–1101, 2003
  31. Franzini A, Marras C, Tringali G, et al: Chronic high frequency stimulation of the posteromedial hypothalamus in facial pain syndromes and behaviour disorders. **Acta Neurochir Suppl** **97**:399–406, 2007
  32. Ghika J, Villemure JG, Miklossy J, et al: Postanoxic generalized dystonia improved by bilateral Voa thalamic deep brain stimulation. **Neurology** **58**:311–313, 2002
  33. Green AL, Wang S, Bittar RG, et al: Deep brain stimulation: a new treatment for hypertension? **J Clin Neurosci** **14**:592–595, 2007
  34. Green AL, Wang S, Owen SL, et al: The periaqueductal grey area and the cardiovascular system. **Acta Neurochir Suppl** **97**:521–528, 2007
  35. Green AL, Wang S, Owen SL, et al: Stimulating the human midbrain to reveal the link between pain and blood pressure. **Pain** **124**:349–359, 2006
  36. Greenberg BD, Gabriels LA, Malone DA Jr, et al: Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. **Mol Psychiatry**, [epub ahead of print], 2008
  37. Greenberg BD, Malone DA, Friehs GM, et al: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. **Neuropsychopharmacology** **31**:2384–2393, 2006
  38. Halpern CH, Wolf JA, Bale TL, et al: Deep brain stimulation in the treatment of obesity. **J Neurosurg** **109**:625–634, 2008
  39. Hamani C, McAndrews MP, Cohn M, et al: Memory enhancement induced by hypothalamic/fornix deep brain stimulation. **Ann Neurol** **63**:119–123, 2008
  40. Hamani C, Moro E: Surgery for other movement disorders: dystonia, tics. **Curr Opin Neurol** **20**:470–476, 2007
  41. Hamani C, Richter E, Schwalb JM, et al: Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. **Neurosurgery** **56**:1313–1314, 2005
  42. Handforth A, DeSalles AA, Krahl SE: Deep brain stimulation of the subthalamic nucleus as adjunct treatment for refractory epilepsy. **Epilepsia** **47**:1239–1241, 2006
  43. Hariz GM, Blomstedt P, Koskinen LO: Long-term effect of deep brain stimulation for essential tremor on activities of daily living and health-related quality of life. **Acta Neurol Scand** **118**:387–394, 2008
  44. Hariz GM, Lindberg M, Bergenheim AT: Impact of thalamic deep brain stimulation on disability and health-related quality of life in patients with essential tremor. **J Neurol Neurosurg Psychiatry** **72**:47–52, 2002
  45. Hernando V, Pastor J, Pedrosa M, et al: Low-frequency bilateral hypothalamic stimulation for treatment of drug-resistant aggressiveness in a young man with mental retardation. **Stereotact Funct Neurosurg** **86**:219–223, 2008

46. Hodaie M, Wennberg RA, Dostrovsky JO, et al: Chronic anterior thalamus stimulation for intractable epilepsy. **Epilepsia** **43**:603–608, 2002
47. Hooper J, Whittle IR: Costs of thalamic deep brain stimulation for movement disorders in patients with multiple sclerosis. **Br J Neurosurg** **17**:40–45, 2003
48. Hosobuchi Y: Subcortical electrical stimulation for control of intractable pain in humans. Report of 122 cases (1970–1984). **J Neurosurg** **64**:543–553, 1986
49. Houeto JL, Karachi C, Mallet L, et al: Tourette's syndrome and deep brain stimulation. **J Neurol Neurosurg Psychiatry** **76**:992–995, 2005
50. Hung SW, Hamani C, Lozano AM, et al: Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. **Neurology** **68**:457–459, 2007
51. Jimenez F, Velasco F, Salin-Pascual R, et al: A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. **Neurosurgery** **57**:585–593, 2005
52. Jimenez F, Velasco F, Salin-Pascual R, et al: Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. **Acta Neurochir Suppl** **97**:393–398, 2007
53. Kerrigan JF, Litt B, Fisher RS, et al: Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy. **Epilepsia** **45**:346–354, 2004
54. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al: The Canadian multicentre study of deep brain stimulation for cervical dystonia. **Brain** **130**:2879–2886, 2007
55. Kleiner-Fisman G, Herzog J, Fisman DN, et al: Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. **Mov Disord** **21** (Suppl 14):S290–S304, 2006
56. Kleiner-Fisman G, Liang GS, Moberg PJ, et al: Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. **J Neurosurg** **107**:29–36, 2007
57. Koller WC, Lyons KE, Wilkinson SB, et al: Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. **Mov Disord** **16**:464–468, 2001
58. Kossoff EH, Ritzl EK, Politsky JM, et al: Effect of an external responsive neurostimulator on seizures and electrographic discharges during subdural electrode monitoring. **Epilepsia** **45**:1560–1567, 2004
59. Krack P, Batir A, Van Blercom N, et al: Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. **N Engl J Med** **349**:1925–1934, 2003
60. Krause M, Fogel W, Kloss M, et al: Pallidal stimulation for dystonia. **Neurosurgery** **55**:1361–1370, 2004
61. Krauss JK, Lohr TJ, Weigel R, et al: Chronic stimulation of the globus pallidus internus for treatment of non-dYT1 generalized dystonia and choreoathetosis: 2-year follow up. **J Neurosurg** **98**:785–792, 2003
62. Kuhn J, Lenartz D, Mai JK, et al: Disappearance of self-aggressive behavior in a brain-injured patient after deep brain stimulation of the hypothalamus: technical case report. **Neurosurgery** **62**:E1182, 2008
63. Kumar K, Toth C, Nath RK: Deep brain stimulation for intractable pain: a 15-year experience. **Neurosurgery** **40**:736–737, 1997
64. Kupsch A, Benecke R, Muller J, et al: Pallidal deep-brain stimulation in primary generalized or segmental dystonia. **N Engl J Med** **355**:1978–1990, 2006
65. Laxton AW, Hamani C, Moro E, et al: Deep brain stimulation and movement disorder treatment, in Squire LR (ed): **Encyclopedia of Neuroscience**. New York: Elsevier, 2009, pp 369–373
66. Lebedev MA, Nicolelis MA: Brain-machine interfaces: past, present and future. **Trends Neurosci** **29**:536–546, 2006
67. Lee KJ, Jang KS, Shon YM: Chronic deep brain stimulation of subthalamic and anterior thalamic nuclei for controlling refractory partial epilepsy. **Acta Neurochir Suppl** **99**:87–91, 2006
68. Leone M, Franzini A, Broggi G, et al: Hypothalamic stimulation for intractable cluster headache: long-term experience. **Neurology** **67**:150–152, 2006
69. Leone M, Franzini A, D'Andrea G, et al: Deep brain stimulation to relieve drug-resistant SUNCT. **Ann Neurol** **57**:924–927, 2005
70. Leuthardt EC, Schalk G, Moran D, et al: The emerging world of motor neuroprosthetics: a neurosurgical perspective. **Neurosurgery** **59**:1–14, 2006
71. Leuthardt EC, Schalk G, Wolpaw JR, et al: A brain-computer interface using electrocorticographic signals in humans. **J Neural Eng** **1**:63–71, 2004
72. Levy RM: Deep brain stimulation for the treatment of intractable pain. **Neurosurg Clin N Am** **14**:389–399, 2003
73. Levy RM, Lamb S, Adams JE: Treatment of chronic pain by deep brain stimulation: long term follow-up and review of the literature. **Neurosurgery** **21**:885–893, 1987
74. Lim AS, Moro E, Lozano AM, et al: Selective enhancement of REM sleep by deep brain stimulation of the human pons. **Ann Neurol** [epub ahead of print], 2009
75. Lim SN, Lee ST, Tsai YT, et al: Electrical stimulation of the anterior nucleus of the thalamus for intractable epilepsy: a long-term follow-up study. **Epilepsia** **48**:342–347, 2007
76. Limousin P, Speelman JD, Gielen F, et al: Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. **J Neurol Neurosurg Psychiatry** **66**:289–296, 1999
77. Loddenkemper T, Pan A, Neme S, et al: Deep brain stimulation in epilepsy. **J Clin Neurophysiol** **18**:514–532, 2001
78. Lozano AM, Mayberg HS, Giacobbe P, et al: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. **Biol Psychiatry** **64**:461–467, 2008
79. Lyons KE, Pahwa R, Busenbark KL, et al: Improvements in daily functioning after deep brain stimulation of the thalamus for intractable tremor. **Mov Disord** **13**:690–692, 1998
80. Maciunas RJ, Maddux BN, Riley DE, et al: Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. **J Neurosurg** **107**:1004–1014, 2007
81. Mallet L, Polosan M, Jaafari N, et al: Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. **N Engl J Med** **359**:2121–2134, 2008
82. Malone DA Jr, Dougherty DD, Rezai AR, et al: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. **Biol Psychiatry** **65**:267–275, 2009
83. Matharu MS, Bartsch T, Ward N, et al: Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. **Brain** **127**:220–230, 2004
84. Mayberg HS, Lozano AM, Voon V, et al: Deep brain stimulation for treatment-resistant depression. **Neuron** **45**:651–660, 2005
85. Mazzone P, Lozano A, Stanzione P, et al: Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. **Neuroreport** **16**:1877–1881, 2005
86. Mehring C, Rickert J, Vaadia E, et al: Inference of hand movements from local field potentials in monkey motor cortex. **Nat Neurosci** **6**:1253–1254, 2003
87. Morrell M: Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures? **Curr Opin Neurol** **19**:164–168, 2006
88. Moss J, Ryder T, Aziz TZ, et al: Electron microscopy of tissue adherent to explanted electrodes in dystonia and Parkinson's disease. **Brain** **127**:2755–2763, 2004
89. Mussa-Ivaldi FA, Miller LE: Brain-machine interfaces: computational demands and clinical needs meet basic neuroscience. **Trends Neurosci** **26**:329–334, 2003

## Current and future perspectives of DBS

90. Nandi D, Aziz T, Carter H, et al: Thalamic field potentials in chronic central pain treated by periventricular gray stimulation—a series of eight cases. **Pain** **101**:97–107, 2003
91. Nuttin B, Cosyns P, Demeulemeester H, et al: Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. **Lancet** **354**:1526, 1999
92. Nuttin BJ, Gabriels LA, Cosyns PR, et al: Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. **Neurosurgery** **52**:1263–1264, 2003
93. Osorio I, Frei MG, Manly BF, et al: An introduction to contingent (closed-loop) brain electrical stimulation for seizure blockage, to ultra-short-term clinical trials, and to multidimensional statistical analysis of therapeutic efficacy. **J Clin Neurophysiol** **18**:533–544, 2001
94. Osorio I, Frei MG, Sunderam S, et al: Automated seizure abatement in humans using electrical stimulation. **Ann Neurol** **57**:258–268, 2005
95. Osorio I, Overman J, Giftakis J, et al: High frequency thalamic stimulation for inoperable mesial temporal epilepsy. **Epilepsia** **48**:1561–1571, 2007
96. Paradiso G, Cunic D, Saint-Cyr JA, et al: Involvement of human thalamus in the preparation of self-paced movement. **Brain** **127**:2717–2731, 2004
97. Paradiso G, Saint-Cyr JA, Lozano AM, et al: Involvement of the human subthalamic nucleus in movement preparation. **Neurology** **61**:1538–1545, 2003
98. Patil PG, Carmena JM, Nicolelis MA, et al: Ensemble recordings of human subcortical neurons as a source of motor control signals for a brain-machine interface. **Neurosurgery** **55**:27–28, 2004
99. Patil PG, Turner DA: The development of brain-machine interface neuroprosthetic devices. **Neurotherapeutics** **5**:137–146, 2008
100. Pereira EA, Muthusamy KA, De Pennington N, et al: Deep brain stimulation of the pedunculopontine nucleus in Parkinson's disease. Preliminary experience at Oxford. **Br J Neurosurg** **22 (1 Suppl)**:S41–S44, 2008
101. Pesaran B, Pezaris JS, Sahani M, et al: Temporal structure in neuronal activity during working memory in macaque parietal cortex. **Nat Neurosci** **5**:805–811, 2002
102. Pilitsis JG, Chu Y, Kordower J, et al: Postmortem study of deep brain stimulation of the anterior thalamus: case report. **Neurosurgery** **62**:E530–E532, 2008
103. Pistohl T, Ball T, Schulze-Bonhage A, et al: Prediction of arm movement trajectories from ECoG-recordings in humans. **J Neurosci Methods** **167**:105–114, 2008
104. Plaha P, Gill SS: Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. **Neuroreport** **16**:1883–1887, 2005
105. Rehncrona S, Johnels B, Widner H, et al: Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments. **Mov Disord** **18**:163–170, 2003
106. Richardson DE, Akil H: Pain reduction by electrical brain stimulation in man. Part 2: Chronic self-administration in the periventricular gray matter. **J Neurosurg** **47**:184–194, 1977
107. Rodriguez MC, Obeso JA, Olanow CW: Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. **Ann Neurol** **44**:S175–S188, 1998
108. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al: Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. **Brain** **128**:2240–2249, 2005
109. Rossi L, Marceglia S, Foffani G, et al: Subthalamic local field potential oscillations during ongoing deep brain stimulation in Parkinson's disease. **Brain Res Bull** **76**:512–521, 2008
110. Sanchez JC, Gunduz A, Carney PR, et al: Extraction and localization of mesoscopic motor control signals for human ECoG neuroprosthetics. **J Neurosci Methods** **167**:63–81, 2008
111. Schiff ND, Giacino JT, Kalmar K, et al: Behavioural improvements with thalamic stimulation after severe traumatic brain injury. **Nature** **448**:600–603, 2007
112. Schlaepfer TE, Cohen MX, Frick C, et al: Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. **Neuropsychopharmacology** **33**:368–377, 2008
113. Schoenen J, Di Clemente L, Vandenhede M, et al: Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. **Brain** **128**:940–947, 2005
114. Schupbach WM, Maltete D, Houeto JL, et al: Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. **Neurology** **68**:267–271, 2007
115. Schuurman PR, Bosch DA, Bossuyt PM, et al: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. **N Engl J Med** **342**:461–468, 2000
116. Schuurman PR, Bosch DA, Merkus MP, et al: Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. **Mov Disord** **23**:1146–1153, 2008
117. Servello D, Porta M, Sassi M, et al: Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. **J Neurol Neurosurg Psychiatry** **79**:136–142, 2008
118. Shahed J, Poysky J, Kenney C, et al: GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. **Neurology** **68**:159–160, 2007
119. Shenoy P, Miller KJ, Ojemann JG, et al: Generalized features for electrocorticographic BCIs. **IEEE Trans Biomed Eng** **55**:273–280, 2008
120. Sramka M, Chkhenkeli SA: Clinical experience in intraoperative determination of brain inhibitory structures and application of implanted neurostimulators in epilepsy. **Stereotact Funct Neurosurg** **54–55**:56–59, 1990
121. Starr PA, Barbaro NM, Raskin NH, et al: Chronic stimulation of the posterior hypothalamic region for cluster headache: technique and 1-year results in four patients. **J Neurosurg** **106**:999–1005, 2007
122. Starr PA, Turner RS, Rau G, et al: Microelectrode-guided implantation of deep brain stimulators into the globus pallidus internus for dystonia: techniques, electrode locations, and outcomes. **J Neurosurg** **104**:488–501, 2006
123. Stefani A, Lozano AM, Peppe A, et al: Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. **Brain** **130**:1596–1607, 2007
124. Stelten BM, Noblesse LH, Ackermans L, et al: The neurosurgical treatment of addiction. **Neurosurg Focus** **25(1)**:E5, 2008
125. Sun FT, Morrell MJ, Wharen RE Jr: Responsive cortical stimulation for the treatment of epilepsy. **Neurotherapeutics** **5**:68–74, 2008
126. Sydow O, Thobois S, Alesch F, et al: Multicentre European study of thalamic stimulation in essential tremor: a six year follow up. **J Neurol Neurosurg Psychiatry** **74**:1387–1391, 2003
127. Tasker RR: Deep brain stimulation is preferable to thalamotomy for tremor suppression. **Surg Neurol** **49**:145–154, 1998
128. Tellez-Zenteno JF, McLachlan RS, Parrent A, et al: Hippocampal electrical stimulation in mesial temporal lobe epilepsy. **Neurology** **66**:1490–1494, 2006
129. Trottenberg T, Volkmann J, Deuschl G, et al: Treatment of severe tardive dystonia with pallidal deep brain stimulation. **Neurology** **64**:344–346, 2005
130. Tsubokawa T, Yamamoto T, Katayama Y, et al: Deep-brain stimulation in a persistent vegetative state: follow-up results and criteria for selection of candidates. **Brain Inj** **4**:315–327, 1990
131. Turnbull IM, Shulman R, Woodhurst WB: Thalamic stimulation for neuropathic pain. **J Neurosurg** **52**:486–493, 1980
132. Umemura A, Jaggi JL, Dolinskas CA, et al: Pallidal deep brain stimulation for longstanding severe generalized dystonia in Hallervorden-Spatz syndrome. Case report. **J Neurosurg** **100**:706–709, 2004
133. Vandewalle V, van der Linden C, Groenewegen HJ, et al:

- Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. **Lancet** **353**:724, 1999
134. Velasco AL, Velasco F, Jimenez F, et al: Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. **Epilepsia** **47**:1203–1212, 2006
  135. Velasco AL, Velasco F, Velasco M, et al: Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study. **Epilepsia** **48**:1895–1903, 2007
  136. Velasco AL, Velasco M, Velasco F, et al: Subacute and chronic electrical stimulation of the hippocampus on intractable temporal lobe seizures: preliminary report. **Arch Med Res** **31**:316–328, 2000
  137. Velasco F, Velasco M, Jimenez F, et al: Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. **Neurosurgery** **47**:295–305, 2000
  138. Velasco F, Velasco M, Ogarrío C, et al: Electrical stimulation of the centromedian thalamic nucleus in the treatment of convulsive seizures: a preliminary report. **Epilepsia** **28**:421–430, 1987
  139. Velasco F, Velasco M, Velasco AL, et al: Effect of chronic electrical stimulation of the centromedian thalamic nuclei on various intractable seizure patterns. I. Clinical seizures and paroxysmal EEG activity. **Epilepsia** **34**:1052–1064, 1993
  140. Velasco M, Velasco F, Velasco AL: Centromedian-thalamic and hippocampal electrical stimulation for the control of intractable epileptic seizures. **J Clin Neurophysiol** **18**:495–513, 2001
  141. Vercueil L, Pollak P, Fraix V, et al: Deep brain stimulation in the treatment of severe dystonia. **J Neurol** **248**:695–700, 2001
  142. Vesper J, Steinhoff B, Rona S, et al: Chronic high-frequency deep brain stimulation of the STN/SNr for progressive myoclonic epilepsy. **Epilepsia** **48**:1984–1989, 2007
  143. Vidailhet M, Vercueil L, Houeto JL, et al: Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. **N Engl J Med** **352**:459–467, 2005
  144. Vidailhet M, Vercueil L, Houeto JL, et al: Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. **Lancet Neurol** **6**:223–229, 2007
  145. Visser-Vandewalle V, Temel Y, Boon P, et al: Chronic bilateral thalamic stimulation: a new therapeutic approach in intractable Tourette syndrome. Report of three cases. **J Neurosurg** **99**:1094–1100, 2003
  146. Vonck K, Boon P, Achten E, et al: Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy. **Ann Neurol** **52**:556–565, 2002
  147. Wallace BA, Ashkan K, Benabid AL: Deep brain stimulation for the treatment of chronic, intractable pain. **Neurosurg Clin N Am** **15**:343–357, 2004
  148. Weaver FM, Follett K, Stern M, et al: Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. **JAMA** **301**:63–73, 2009
  149. Weinberger M, Hamani C, Hutchison WD, et al: Pedunculo-pontine nucleus microelectrode recordings in movement disorder patients. **Exp Brain Res** **188**:165–174, 2008
  150. Welter ML, Mallet L, Houeto JL, et al: Internal pallidal and thalamic stimulation in patients with Tourette syndrome. **Arch Neurol** **65**:952–957, 2008
  151. Wohrle JC, Weigel R, Grips E, et al: Risperidone-responsive segmental dystonia and pallidal deep brain stimulation. **Neurology** **61**:546–548, 2003
  152. Yamamoto T, Katayama Y, Kobayashi K, et al: DBS therapy for a persistent vegetative state: ten years follow-up results. **Acta Neurochir Suppl** **87**:15–18, 2003
  153. Yamamoto T, Katayama Y, Oshima H, et al: Deep brain stimulation therapy for a persistent vegetative state. **Acta Neurochir Suppl** **79**:79–82, 2002

---

Manuscript submitted March 15, 2009.

Accepted April 30, 2009.

*Address correspondence to:* Clement Hamani, M.D., Ph.D., Division of Neurosurgery, Toronto Western Hospital, 399 Bathurst Street, 4<sup>th</sup> floor, Toronto, Ontario, Canada WW4-437. email: Clement.Hamani@uhn.on.ca.